Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder

Abstract

Background The National Institute for Occupational Safety and Health (NIOSH) conducted a health hazard evaluation (HHE) of a water‐damaged school in New Orleans (NO), Louisiana. Our aim in this evaluation was to document employee health effects related to exposure to the water‐damaged school, and to determine if VCS testing could serve as a biomarker of effect for occupants who experienced adverse health effects in a water‐damaged building. Methods NIOSH physicians and staff administered a work history and medical questionnaire, conducted visual contrast sensitivity (VCS) testing, and collected sticky‐tape, air, and dust samples at the school. Counting, culturing, and/or a DNA‐based technology, called mold‐specific quantitative PCR (MSQPCR), were also used to quantify the molds. A similar health and environmental evaluation was performed at a comparable school in Cincinnati, Ohio which was not water‐damaged. Results Extensive mold contamination was documented in the water‐damaged school and employees (n = 95) had higher prevalences of work‐related rashes and nasal, lower respiratory, and constitutional symptoms than those at the comparison school (n = 110). VCS values across all spatial frequencies were lower among employees at the water‐damaged school. Conclusions Employees exposed to an extensively water‐damaged environment reported adverse health effects, including rashes and nasal, lower respiratory, and constitutional symptoms. VCS values were lower in the employees at the water‐damaged school, but we do not recommend using it in evaluation of people exposed to mold. Am. J. Ind. Med. 55:844–854, 2012. This article is a U.S. Government work and is in the public domain in the USA.

Pseudomyxoma Peritonei Originating from Urachus—Case Report and Review of the Literature

“…As mentioned earlier, peritoneal spread and local invasiveness are essential and defining for pmp, and surgical management (radical or partial cystectomy with en block resection of tumour, urachal remnant, umbilicus, and posterior rectus abdominus facia) might be insufficient for urachal adenocarcinoma 49 .…”

“…The second independent prognostic factor is the histologic grade of the causative malignant lesion 2,7,35,[41][42][43]49 . According to data published by Ronnett and colleagues 7 , the 5-year survival rate in patients with pmp of appendical origin is 84% for patients with dpam, 37.6% for patients whose lesions have intermediate features, and only 6.7% for patients with pmca.…”

Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature

“…At present, it remains unclear whether the survival of patients with urachal adenocarcinoma varies from that of patients with non-urachal adenocarcinomas. Wright et al (19) identified that urachal cancer possessed a significantly better prognosis than non-urachal cancer, while Mostofi et al (20) hypothesized that urachal adenocarcinomas were associated with a significantly worse prognosis. In addition, Dandekar et al (21) considered there to be no significant differences between the two carcinomas.…”

Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report

“…4 In contrast with the much more frequent transitional cell cancers of the bladder, urachal cancer typically occurs in a younger patient population, with many reports indicating a median age at diagnosis of approximately 47-56 years. [2][3][4] While some investigators report a predominantly male patient population, 5 others suggest a more balanced distribution between male and female patients. 3,4 Unfortunately, there are many patients who present with metastatic disease which currently is not likely to be curable.…”

“…[2][3][4] While some investigators report a predominantly male patient population, 5 others suggest a more balanced distribution between male and female patients. 3,4 Unfortunately, there are many patients who present with metastatic disease which currently is not likely to be curable. There is no standard chemotherapy regimen for these patients.…”